| 货号 | 18924-1mg |
| 描述 | ONO-4059 analog is the [(3S)-1-(1-oxo-2-propen-1-yl)-3-piperidinyl] analog of the recently published structure of ONO-4059.1 ONO-4059 is an orally bioavailable inhibitor of Bruton’s tyrosine kinase (BTK; IC50 = 2.2 nM), a non-receptor tyrosine kinase involved in signal transduction pathways regulating the proliferation, activation, and differentiation of B cells.2 ONO-4059 reversibly blocks B cell receptor signaling and B cell proliferation and activation.2 ONO-4059 suppresses the generation of inflammatory chemokines and cytokines in a mouse model of collagen-induced arthritis, resulting in regression of cartilage erosion, bone damage, and pannus formation.2 ONO-4059 is in clinical trials concerning certain leukemias and lymphomas, including chronic lymphocytic leukemia.3,4,1 The actions of ONO-4059 analog have not been studied. |
| 别名 | GS-4059 analog; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Walter, H.S.,Rule, S.A.,Dyer, M.J.S., et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood 127(4), 411-419 (2016). 2.Akinleye, A.,Chen, Y.,Mukhi, N., et al. Ibrutinib and novel BTK inhibitors in clinical development. J. Hematol. Oncol. 6(59), (2013). 3.Burger, A. Bruton’s tyrosine kinase (BTK) inhibitors in clinical trials. Curr.Hematol.Maliq.Rep. 9(1), 44-49 (2014). 4.Robak, P.,Smolewski, P., and Robak, T. Emerging immunological drugs for chronic lymphocytic leukemia. Expert Opin.Emerg.Drugs 20(3), 423-447 (2015). | |
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 456.5 |
| 分子式 | C25H24N6O3 |
| CAS号 | 1351635-67-0 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |